AbCellera Biologics (ABCL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.18
- EPS estimate
- −$0.14
- EPS surprise
- −24.74%
- Revenue surprise
- −48.39%
- Revenue
- $4.0M
- Revenue estimate
- $7.8M
- Reported
- Aug 5, 2026
AbCellera reported Q2 2026 results on August 5, 2026. It posted a loss of $0.18 per share, wider than the expected loss of $0.14, a 24.74% miss. Revenue was $4.0 million, about half the $7.8 million estimate. A year earlier, in Q2 2025, the loss was $0.12 per share and revenue was $17.1 million, so revenue fell about 77%.
The table shows two different periods. In 2022, AbCellera earned $0.50 per share on $485.4 million of revenue, with Q1 2022 the peak at $0.54 and $316.6 million. Since Q4 2022, every quarter has been a loss. Full-year losses were $0.51 per share in 2023, $0.56 in 2024 and $0.49 in 2025. Revenue has been small and uneven, from $4.0 million in Q2 2026, the low in the table, to $44.9 million in Q4 2025. Over the last 20 quarters, AbCellera beat the EPS estimate 8 times and missed 12 times.
AbCellera reported Q3 results between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether quarterly losses stay in the range of recent years and how revenue compares with the low Q2 figure.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.14 | −$0.18 | −24.74% | $4.0M | SEC |
| Q1 2026 | May 11, 2026 | −$0.17 | −$0.14 | +18.32% | $8.3M | SEC |
| Q4 2025 | Feb 24, 2026 | −$0.13 | −$0.03 | +77.61% | $44.9M | SEC |
| Q3 2025 | Nov 6, 2025 | −$0.14 | −$0.19 | −36.89% | $9.0M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.13 | −$0.12 | +10.58% | $17.1M | SEC |
| Q1 2025 | May 8, 2025 | −$0.14 | −$0.15 | −10.21% | $4.2M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.13 | −$0.12 | +9.98% | $5.1M | SEC |
| Q3 2024 | Nov 4, 2024 | −$0.12 | −$0.17 | −36.66% | $6.5M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.12 | −$0.13 | −8.33% | $7.3M | SEC |
| Q1 2024 | May 7, 2024 | −$0.13 | −$0.14 | −11.55% | $10.0M | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.11 | −$0.16 | −39.25% | $9.2M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.12 | −$0.10 | +17.42% | $6.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.13 | −$0.11 | +18.09% | $10.1M | SEC |
| Q1 2023 | May 4, 2023 | −$0.13 | −$0.14 | −8.86% | $12.2M | SEC |
| Q4 2022 | Feb 21, 2023 | $0.01 | −$0.10 | −1130.93% | $21.5M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.06 | $0.08 | +27.59% | $101.4M | SEC |
| Q2 2022 | Aug 9, 2022 | $0.00 | −$0.02 | −766.67% | $45.9M | SEC |
| Q1 2022 | May 10, 2022 | $0.40 | $0.54 | +35.51% | $316.6M | SEC |
| Q4 2021 | Feb 24, 2022 | $0.20 | $0.19 | −6.82% | $139.3M | — |
| Q3 2021 | Nov 9, 2021 | −$0.04 | −$0.08 | −128.57% | $5.5M | SEC |
Quarterly revenue
Frequently asked questions
When did AbCellera Biologics (ABCL) last report earnings?
AbCellera Biologics last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ABCL beat earnings estimates?
No. AbCellera Biologics reported EPS of −$0.18 for Q2 2026 against a −$0.14 estimate — a 24.74% miss.
How much revenue did ABCL report last quarter?
AbCellera Biologics reported $4.0M in revenue for Q2 2026, against a consensus estimate of $7.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.